rs9394502 — BTBD9 BTBD9 insomnia/RLS variant

BTBD9 — The Iron–Sleep Connection

BTBD9 encodes a BTB/POZ domain-containing protein¹¹ BTB/POZ domain-containing protein
A protein scaffold that bridges substrates to the CUL3-RBX1 E3 ubiquitin ligase complex, marking target proteins for proteasomal degradation that controls how quickly certain proteins are cleared from cells. In the brain, BTBD9 appears to regulate iron homeostasis in dopaminergic pathways — the same system responsible for dopamine signalling in motor circuits and the rest-activity cycle. This makes BTBD9 the molecular bridge between two seemingly unrelated complaints: difficulty falling asleep, and an irresistible urge to move the legs at rest.

The rs9394502 variant sits in an intron of BTBD9 and acts as a tag SNP²² tag SNP
A marker in strong linkage disequilibrium with one or more functional variants; it travels with the causal allele through generations even if it isn't causal itself for the risk haplotype. People carrying one or two T alleles show measurably higher rates of insomnia and restless legs syndrome in some of the largest genetic studies ever conducted.

The Mechanism

BTBD9 functions as a substrate adaptor for the CUL3-based E3 ubiquitin ligase complex, targeting specific proteins for proteasomal degradation. In Drosophila, loss-of-function models of the BTBD9 homologue produce periodic leg movements and reduced dopamine levels — the core features of RLS — suggesting the protein controls dopamine turnover in motor circuits.

The iron connection is direct: iron is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. BTBD9 polymorphisms are significantly associated with serum ferritin levels in population studies, indicating that the protein influences systemic iron storage or turnover. When BTBD9 function is perturbed, iron homeostasis shifts, dopamine synthesis capacity falls, and the sensorimotor circuits controlling limb movements at rest become dysregulated — producing the classic RLS symptoms that are worst at night, when dopamine levels naturally dip to their daily minimum.

Insomnia and RLS share this biological substrate: both worsen when brain iron is low, both respond to iron repletion when ferritin is deficient, and both are enriched among carriers of BTBD9 risk variants.

The Evidence

The insomnia association was established at genome-wide significance by Jansen et al. 2019³³ Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet, 2019;51:394-403. In 1,331,010 individuals — one of the largest psychiatric GWAS at the time — rs9394502 reached p=8×10⁻¹⁸ with an odds ratio of 1.056 (95% CI 1.04–1.07). The modest per-allele effect size (5.6% increased odds per T allele) is typical for common polygenic risk variants; the significance is extraordinary because the sample is enormous.

The finding was independently replicated by Watanabe et al. 2022⁴⁴ Watanabe et al. 2022
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet, 2022;54:1125-1132 in an even larger meta-analysis (593,724 cases, 1,771,286 controls), where rs9394502 surpassed p=4×10⁻²⁰ — five orders of magnitude below the genome-wide significance threshold.

BTBD9's role in restless legs syndrome was established earlier. Winkelmann et al. 2007⁵⁵ Winkelmann et al. 2007
Winkelmann J et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet, 2007;39:1000-6 reported BTBD9 as one of three genome-wide significant RLS loci, with each risk variant conferring more than 50% increased risk for RLS. Subsequent studies confirmed that BTBD9 risk alleles also associate with periodic limb movements of sleep (PLMS), a closely related motor phenotype that disrupts sleep architecture even when the person is unaware of it.

Practical Actions

For T allele carriers — particularly TT homozygotes — the most directly actionable intervention is iron status assessment. Clinical guidelines for RLS recommend checking serum ferritin and targeting levels above 75 ng/mL (some guidelines recommend 100 ng/mL) because brain iron deficiency drives symptoms even when hemoglobin is normal. This is a genotype-specific monitoring threshold: the general population guideline for iron deficiency (ferritin <12 ng/mL) dramatically underestimates the brain iron requirement in susceptible individuals.

For TT carriers with confirmed RLS, oral ferrous sulfate (325 mg every other day on an empty stomach) is the standard first-line approach when ferritin is below 75 ng/mL. For those who cannot tolerate oral iron or have malabsorption, intravenous ferric carboxymaltose produces faster and more sustained ferritin rises.

Interactions

The BTBD9 risk haplotype shows strongest effect when combined with other RLS-associated variants. rs3923809 (also in BTBD9) is in partial linkage disequilibrium with rs9394502; carriers of both risk alleles show stronger periodic limb movement severity. MEIS1 rs2300478 on chromosome 2p encodes a transcription factor in the same developmental pathway as BTBD9 and independently triples RLS risk — combined MEIS1 + BTBD9 risk genotypes are found in a substantial fraction of diagnosed RLS patients. MAP2K5 rs6494696 represents a third independent RLS locus identified in the same 2007 GWAS. Each locus acts additively; the compound risk from multiple BTBD9 + MEIS1 + MAP2K5 risk genotypes is an active area of research and a natural candidate for compound action entries.